Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Gains from Sales and Divestitures (2018 - 2019)

Rockwell Medical (RMTI) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $96542.0 as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Gains from Sales and Divestitures changed N/A year-over-year to $96542.0, compared with a TTM value of $96542.0 through Sep 2019, changed N/A, and an annual FY2018 reading of $98500.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $96542.0 for Q3 2019 at Rockwell Medical, down from $98500.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $98500.0 in Q4 2018 and bottomed at $96542.0 in Q3 2019.